KemPharm Inc (KMPH) : Dsc Advisors scooped up 92,301 additional shares in KemPharm Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 893,558 shares of KemPharm Inc which is valued at $3,583,168.KemPharm Inc makes up approximately 2.23% of Dsc Advisors’s portfolio.
Other Hedge Funds, Including , Millennium Management added KMPH to its portfolio by purchasing 23,296 company shares during the most recent quarter which is valued at $93,417. Tower Research Capital (trc) sold out all of its stake in KMPH during the most recent quarter. The investment firm sold 689 shares of KMPH which is valued $2,763. Sphera Funds Management Ltd. sold out all of its stake in KMPH during the most recent quarter. The investment firm sold 183,954 shares of KMPH which is valued $737,656. Dekabank Deutsche Girozentrale sold out all of its stake in KMPH during the most recent quarter. The investment firm sold 6,600 shares of KMPH which is valued $27,324.
KemPharm Inc opened for trading at $4.82 and hit $5.05 on the upside on Wednesday, eventually ending the session at $4.85, with a gain of 1.68% or 0.08 points. The heightened volatility saw the trading volume jump to 40,669 shares. Company has a market cap of $71 M.
KemPharm Inc. is a United States-based clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of new molecular entity (NME) prodrugs. The Company through its Ligand Activated Therapy (LAT) platform technology creates NME prodrug product candidates. The Company’s NME prodrug product candidates include KP201/APAP KP511/ER and KP606/ER for the treatment of pain; KP415 for the treatment of attention deficit hyperactivity disorder (ADHD) and KP303 for the treatment of central nervous system (CNS) disorders. The Company’s product’s KP201/APAP is in clinical trial stage and KP511/ER KP415 KP606/ER and KP303 are in preclinical trail stage.